文献速递瓣膜外科

经导管主动脉瓣置换术后抗栓治疗的疗效与安全性:系统评价与网状Meta分析

Comparative efficacy and safety of antithrombotic therapy for transcatheter aortic valve replacement: a systematic review and network meta-analysis.
PubMed 文献 · Eur J Cardiothorac Surg · 2020-01-01

该系统评价与网状Meta分析纳入8项研究共2173例患者,比较经导管主动脉瓣置换术后不同抗栓方案。结果显示双联抗血小板治疗较单联抗血小板治疗增加30天出血风险(OR 1.90),但卒中与死亡率无差异;双联抗血小板联合口服抗凝药出血风险最高,应避免。

要点

  • 双联抗血小板治疗较单联增加30天出血风险(OR 1.90),卒中与死亡率无差异。
  • 双联抗血小板联合口服抗凝药出血风险最高,较单联增加(OR 6.21),应避免。
  • 口服抗凝药在30天出血与卒中平衡上可能优于单联或双联抗血小板治疗。

核心结论

  • 单联抗血小板治疗有减少出血趋势,但双联抗血小板治疗未显示死亡率获益。
  • 口服抗凝药可能改善卒中与出血的平衡,从而降低死亡风险。
  • 双联抗血小板联合口服抗凝药出血风险最高,应避免使用。

研究设计与样本

  • 纳入8项研究共2173例患者,评估30天出血、卒中及全因死亡。
  • 采用SUCRA曲线排序治疗,GRADE方法评价证据质量,PROSPERO注册号CRD42018111163。

关键数值与推荐

  • 双联抗血小板联合口服抗凝药30天出血风险SUCRA为1.0%,排名最差。
  • 30天出血SUCRA:口服抗凝药86.3%,单联抗血小板治疗72.3%,双联抗血小板治疗32.3%。
  • 30天卒中SUCRA:口服抗凝药54.2%,单联抗血小板治疗47.4%,双联抗血小板治疗40.5%。
  • 30天死亡率SUCRA:口服抗凝药69.6%,单联抗血小板治疗74.1%,双联抗血小板治疗43.4%。

临床怎么用

  • 经导管主动脉瓣置换术后抗栓策略应优先考虑单联抗血小板治疗以减少出血。
  • 避免使用双联抗血小板联合口服抗凝药,因其出血风险显著增加。
  • 口服抗凝药可能作为平衡卒中与出血的选项,但需个体化评估。

局限性

  • 纳入研究数量有限(8项),样本量2173例,可能影响结论稳健性。
  • 网状Meta分析基于间接比较,存在异质性与偏倚风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We sought to determine the optimal antithrombotic therapy after transcatheter aortic valve replacement. METHODS: Related scientific databases were searched until December 2018. We conducted a pairwise and a network meta-analysis within a frequentist framework, measuring 30-day bleeding, stroke and all-cause mortality. The surface under the cumulative ranking (SUCRA) curve was estimated to rank the therapies. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was performed. The protocol was registered with PROSPERO (CRD42018111163). RESULTS: Eight studies comprising 2173 patients were analysed. The risk of 30-day bleeding was higher for dual antiplatelet therapy (DAPT) than single antiplatelet therapy (SAPT) [odds ratio (OR) 1.90 (1.10-3.28); P = 0.02], whereas there was no difference in the risk of 30-day stroke [OR 1.27 (0.38-4.20); P = 0.69] and mortality [OR 1.46 (0.67-3.22); P = 0.34] between DAPT and SAPT. In the network meta-analysis, DAPT + oral anticoagulant (OAC) increased the risk of 30-day bleeding compared with SAPT [OR 6.21 (1.74-22.17); P = 0.005], DAPT [OR 3.27 (1.04-10.32); P = 0.043], SAPT + OAC [OR 4.87 (2.51-9.45); P < 0.001] and OAC [OR 14.4 (1.3-154.7); P = 0.028]. Additionally, patients receiving DAPT + OAC had the highest risks for 30-day bleeding (SUCRA 1.0%). OAC seemed to be superior to SAPT and DAPT in terms of 30-day bleeding (SUCRA OAC: 86.3%, SAPT: 72.3%, DAPT: 32.3%) and stroke (SUCRA 54.2%, 47.4%, 40.5%), but not mortality (SUCRA 69.6%, 74.1%, 43.4%). CONCLUSIONS: There is a trend towards less bleeding with the application of SAPT, but no mortality benefit with the application of DAPT is shown. The comparison of SAPT, DAPT and OAC shows that OAC may improve the balance between stroke and bleeding, which can reduce the risk of mortality. In addition, the application of DAPT + OAC was ranked the worst amongst all treatment modalities and should be avoided due to an increased risk of bleeding. CLINICAL TRIAL REGISTRATION NUMBER: PROSPERO (International Prospective Register of Systematic Reviews, CRD42018111163).

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Zhu Y, Zou Z, Huang Y, et al. Comparative efficacy and safety of antithrombotic therapy for transcatheter aortic valve replacement: a systematic review and network meta-analysis. Eur J Cardiothorac Surg. 2020. PMID: 31883333. doi:10.1093/ejcts/ezz335

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。